Tuberculosis - Apr 29, 2024 - 154 million lives saved: Landmark study highlights power of vaccination

Can't see this email? View it online

	Tuberculosis
	The latest tuberculosis news from News Medical

	154 million lives saved: Landmark study highlights power of vaccination A major landmark study to be published by The Lancet reveals that global immunization efforts have saved an estimated 154 million lives – or the equivalent of 6 lives every minute of every year – over the past 50 years.

	Study reveals lasting lung damage in tuberculosis survivors New research being presented at this year's ESCMID Global Congress (formerly ECCMID) in Barcelona, Spain (27-30 April) has found compelling evidence that tuberculosis (TB) can have a lasting impact on the lungs of individuals who have been successfully treated for the disease.

			Undernourished household contacts three times more likely to develop TB Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB), is distinct from most germs in its capacity to silently infect individuals for months and even years before waking up and causing active disease that can lead to severe illness and death.

			Revvity unveils a new era of automated tuberculosis testing Revvity, Inc. (NYSE: RVTY) today announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test. The Auto-Pure 2400 platform is easy to use and designed to provide efficient workflows in the lab. When the accuracy of the T-SPOT.TB test is combined with the efficiency of the Auto-Pure 2400 system, labs, clinicians and ultimately patients, benefit from the resultant powerful solution.

	The path to a better tuberculosis vaccine runs through Montana A team of Montana researchers is playing a key role in the development of a more effective vaccine against tuberculosis, an infectious disease that has killed more people than any other.

	Harnessing immune enhancement to combat drug-resistant tuberculosis Experts are working on novel immune-enhancing therapies called host-directed therapies to use the body's own immune system to target tuberculosis, with hopes that they could tackle even the drug-resistant forms of the disease.

	Owlstone Medical secures $6.5 million to support development of breath-based diagnostics for infectious disease Funding represents the first time the foundation has taken an equity position in a breath diagnostics company.

Website: www.news-medical.net

Email: [email protected]

Telephone: +44 (0)161 457 7150

AZoNetwork UK Ltd.
NEO, 4th Floor
9 Charlotte Street, Manchester
M1 4ET, UK

Why did you receive this email?
You recently requested related information from us and asked to be notified of additional information.

Not interested anymore?
Unsubscribe or
Update Your Newsletter Subscriptions